Surgery Without Cuts Gets $25M+ for Human Trials

Imagine undergoing surgery with no cuts, no pain, and no scars while your body heals itself naturally. That future just moved closer to reality as Petal Surgical announced new funding to advance its revolutionary incisionless surgery platform toward human trials.

The company uses a technology called acoustic liquefaction, which harnesses focused ultrasound waves to treat tissue without any cutting. Blue Pool Capital led this latest investment round, joining heavyweight backers including Dr. Fred Moll, considered the father of surgical robotics and co-founder of Intuitive Surgical.

Petal has now raised over $25 million since emerging from stealth last fall. The company combines ultrasound technology with artificial intelligence and robotics to create what it calls Millisecond Pulse Histotripsy, a precise method that destroys abnormal tissue one tiny vapor-filled cavity at a time.

The process works with the body's natural healing abilities rather than against them. Traditional surgery cuts through healthy tissue to reach problem areas, creating trauma that takes weeks or months to heal. Petal's approach eliminates the blade entirely, meaning no incisions, no burns, and none of the typical surgical risks like infection or scarring.

The company plans to use its new funds to accelerate research and development, expand clinical readiness activities, and prepare for first-in-human studies. A team of renowned medical innovators founded Petal, including neurosurgeon Dr. Bowen Jiang, robotic spine surgery pioneer Dr. Nicholas Theodore, and Rony Abovitz, who founded Mako Surgical before Stryker acquired it.

Why This Inspires

This breakthrough represents more than just a technical achievement. For millions of people who avoid necessary procedures due to fear of surgery, this could be life-changing. Elderly patients who can't tolerate traditional operations might suddenly have treatment options. People in remote areas with limited surgical facilities could access advanced care without traveling to major medical centers.

The technology also addresses a fundamental truth about medicine: the less we traumatize the body during treatment, the faster and better it heals. By working with natural healing processes instead of creating damage that needs repair, incisionless surgery could set a new standard for what patients should expect from medical procedures.

Christopher Wu, chief investment officer at Blue Pool Capital, captured the significance perfectly: "We invest in innovative market leaders who have bigger ambitions than incremental change. In Petal we see a big opportunity to change and improve healthcare."

As Petal moves toward human trials, the promise is clear: surgery that treats the problem without creating new ones, making advanced care safer and more accessible for everyone.